In recent years, sodium-glucose cotransporter 2 (SGLT-2) inhibitors have gained attention as a novel class of antidiabetic drugs, particularly due to their significant efficacy in diabetic nephropathy (5). This evidence concerns the gene SLC5A2 and diabetic kidney disease.